InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Aspire Biopharma Holdings, Inc.

ASBP Clue Score19
United States Fiscal year ends December CIK 0001847345
$8.30 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $8.30 −21.77% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Apr 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Net income3.3Fiscal year 2023Net income4.5 +33.6%Fiscal year 2024Operating income−1.2Net income−1.3 −129.3%EPS, diluted−1.90Fiscal year 2025Revenue0.0Operating income−19.4Net income−24.5EPS, diluted−16.38
FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a 0.0
Growth
Operating income n/a n/a −1.2 −19.4
Net income 3.3 4.5 −1.3 −24.5
Growth +33.6% −129.3%
EPS, diluted n/a n/a −1.90 −16.38

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025Gross margin−1.9%Operating margin−312,016.9%Net margin−394,725.1%
FY2022FY2023FY2024FY2025
Gross margin n/a n/a n/a −1.9%
Operating margin n/a n/a n/a −312,016.9%
Net margin n/a n/a n/a −394,725.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−1.4Fiscal year 2023Operating cash flow−0.7Buybacks−284.9Fiscal year 2024Operating cash flow−0.3Buybacks−13.8Fiscal year 2025Operating cash flow−4.9
FY2022FY2023FY2024FY2025
Operating cash flow −1.4 −0.7 −0.3 −4.9
Buybacks n/a −284.9 −13.8 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.5Shareholders’ equity−9.9Fiscal year 2023Cash0.0Shareholders’ equity−0.5Fiscal year 2024Cash0.0Shareholders’ equity−1.5Fiscal year 2025Cash1.0Shareholders’ equity−6.4
FY2022FY2023FY2024FY2025
Cash 0.5 0.0 0.0 1.0
Shareholders’ equity −9.9 −0.5 −1.5 −6.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−1.4 −0.7 −0.3 −4.9
Growth
Investment
−294.7 284.9 13.8 n/a
Financing
296.6 −284.8 0.3 5.9
n/a −284.9 −13.8 n/a

Capital expenditure, dividends and buybacks are shown as money out, so negative.